Recent progress in development of cyclin-dependent kinase 7 inhibitors for cancer therapy.

Hanzhi Liang, Jintong Du, Reham M Elhassan, Xuben Hou, Hao Fang

Expert opinion on investigational drugs 2021 Jan

filter terms:

Introduction: Cyclin-dependent kinase 7 (CDK7) is a part of the CDK-activating kinase family (CAK) which has a key role in the cell cycle and transcriptional regulation. Several lines of evidence suggest that CDK7 is a promising therapeutic target for cancer. CDK7 selective inhibitors such as SY-5609 and CT7001 are in clinical development. Areas covered: We explore the biology of CDK7 and its role in cancer and follow this with an evaluation of the preclinical and clinical progress of CDK7 inhibitors, and their potential in the clinic. We searched PubMed and ClinicalTrials to identify relevant data from the database inception to 14 October 2020. Expert opinion: CDK7 inhibitors are next generation therapeutics for cancer. However, there are still challenges which include selectively, side effects, and drug resistance. Nevertheless, with ongoing clinical development of these inhibitors and greater analysis of their target, CDK7 inhibitors will become a promising approach for treatment of cancer in the near future.

Citation

Hanzhi Liang, Jintong Du, Reham M Elhassan, Xuben Hou, Hao Fang. Recent progress in development of cyclin-dependent kinase 7 inhibitors for cancer therapy. Expert opinion on investigational drugs. 2021 Jan;30(1):61-76